Long-term antibiotics for Chronic Rhinosinusitis: changing views
performed and systematically reviewed which showed no effect after three months of macrolide treatment (1) . Furthermore, in recent years there has been considerable debate around the potential increased risks of cardiovascular events extending at least a year beyond exposure to the antibiotic (2) . In this issue of Contrary to these unclear results in CRS, in the lower airways, and especially in COPD, a clear reduction of exacerbations has been found in patients with unstable disease (3) . The total number of patients evaluated, however, was much larger (3170 patients). One of the reasons of these differences in findings might be different pheno-and endotype of disease. In his first trial Wallwork has already highlighted potential differences in phenotype that might predict the effect of macrolides, with patients with low IgE having a better outcome, and recently a number of uncontrolled evaluations point to a potentially larger effect of long-term antibiotics in patients with non-Th2 forms of the disease (4, 5) . The study in this Journal pointing at a shift towards eosinophilic inflammation, and away from nonTh2 forms of CRS in Asia in the last decade, may explain why, especially in Asia, macrolide therapy has been very successful in the past, although it could currently be expected to be less effective in that region (6) . predictors of success (7) . The other factors were not helpful, particularly in the postoperative period, where there does not seem to be an additive effect of macrolides over nasal corticosteroids alone (7, 8) . Recently it was proposed to systematically use eosinophils (as a marker of Th2 disease) on top of phenotyping based on the presence of nasal polyps, to differentiate treatments in CRS (9) . In EPOS2012, we decided to present long-term macrolides as an option although the evidence was thin. The upcoming EPOS2020 will again give a full systematic review of the relevant literature to help you to decide on the best treatment for your patients. For now, it is a close call to determine whether to prescribe macrolides and to whom.
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